

News Release

Meiji Seika Pharma Co., Ltd.
Daito Pharmaceutical Co., Ltd.

June 4, 2025

Meiji Seika Pharma and Daito Pharmaceutical Initiate Dialogue on Collaboration Toward Establishing a Novel Consortium for the Realignment of Generic Pharmaceutical Manufacturers

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo, Japan; President and Representative Director: Daikichiro Kobayashi) and Daito Pharmaceutical Co., Ltd. (headquartered in Toyama, Japan; President and CEO: Hiroshi Matsumori) announced today that their agreement to initiate dialogue on collaboration, including product integration, toward realizing the “Consortium Initiative” among multiple generic pharmaceutical companies.



Mr. Kobayashi, President of Meiji Seika Pharma ; Mr. Matsumori, President of Daito Pharmaceutical.

News Release

The two companies will promote the consolidation of production facilities among multiple generic pharmaceutical companies participating in the Consortium Initiative. This will improve production efficiency and enhance the quality management systems of all participating companies in the consortium through mutual inspection and verification. Furthermore, the standardizing of product names and consolidating sales items will lead to a stable supply of generic drugs and an improved profit structure for all participating companies. Meiji Seika Pharma and Daito Pharmaceutical will share these strategies and serve as a core function in the realignment of the generic pharmaceutical industry.

As the first step in this initiative, the two companies will consolidate the production sites for the generic drugs associated with their sales. Moving forward, the participating companies will consolidate the production sites of the generic drugs involved in each company's sales and proceed with negotiations aimed at further product integration. This initiative does not necessarily aim to establish a corporation for functional integration.

Meiji Seika Pharma and Daito Pharmaceutical are committed to building a sustainable supply system for generic pharmaceuticals in line with the novel consortium initiative. Both companies will undertake this effort as pioneers in the realignment of the generic pharmaceutical industry.

